These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34133062)

  • 1. Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis.
    Sajmi S; Goutham K; Arumugam V; Gopalakrishnan N; Lamech TM; Aiswarya D; Krishna R; Vathsalyan P; Kannan BS; Solomon D; Nithya G; Sastry BVRH; Sakthirajan R
    Hemodial Int; 2021 Oct; 25(4):515-522. PubMed ID: 34133062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience.
    Cusi MG; Conticini E; Gandolfo C; Anichini G; Savellini GG; Valente S; Franchi F; Scolletta S; Percivalle E; Frediani B
    BMC Infect Dis; 2021 Jul; 21(1):630. PubMed ID: 34210259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
    JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection.
    Baldeón ME; Maldonado A; Ochoa-Andrade M; Largo C; Pesantez M; Herdoiza M; Granja G; Bonifaz M; Espejo H; Mora F; Abril-López P; Armijo LKR; Pacheco V; Salazar R; Reinthaller S; Zertuche F; Fornasini M
    Transfus Med; 2022 Apr; 32(2):153-161. PubMed ID: 35001439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
    Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
    Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study.
    Ghadami L; Hasibi M; Asadollahi-Amin A; Asanjarani B; Farahmand M; Abdollahi H
    Microb Pathog; 2022 Apr; 165():105482. PubMed ID: 35288278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study.
    Tworek A; Jaroń K; Uszyńska-Kałuża B; Rydzewski A; Gil R; Deptała A; Franek E; Wójtowicz R; Życińska K; Walecka I; Cicha M; Wierzba W; Zaczyński A; Król ZJ; Rydzewska G
    Int J Infect Dis; 2021 Apr; 105():209-215. PubMed ID: 33607305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection.
    Escobedo-Sánchez PE; de la Cruz-Hernández I; Ramos-García M; Sánchez-Yedra I; García-Vázquez C; Guzmán-Priego CG; García-Vidrios MV; Olvera-Hernández V; Mendoza-García Y; Ble-Castillo JL
    Med Clin (Barc); 2023 Oct; 161(8):323-329. PubMed ID: 37423879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of the results of convalescent plasma therapy applied to pregnant women diagnosed as COVID-19- positive in a pandemic center: A prospective cohort study.
    Erol SA; Tanaçan A; Apaydın H; Ayhan ŞG; Oluklu D; Hendem DU; Ünlü S; Erden A; Tekin ÖM; Omma A; Ateş İ; Küçükşahin O; Şahin D
    Turk J Med Sci; 2022 Jun; 52(3):554-564. PubMed ID: 36326345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.